Thursday, February 19, 2026 at 12-1pm ET                        Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Advances in Alzheimer's disease (AD) diagnostics are reshaping clinical practice, making early and precise detection possible.

Explore the latest clinical insights related to blood-based biomarkers, which include their importance in AD and appropriate utilization for patient care.

During this session, we will review AD pathophysiology and the types of blood-based biomarkers, and discuss the topics below:

• The role blood-based biomarkers play in early, accurate, and accessible AD diagnosis.
• Strategies for identifying patients in the early stages of AD and selecting appropriate patients for blood-based biomarker testing.
• Approaches to utilizing blood-based biomarker testing for the patient's AD journey.
• The use of structural imaging, amyloid positron emission tomography (PET), and cerebrospinal fluid (CSF) for detection of AD-related pathological changes.
• The economic value of AD blood-based biomarker implementation.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.